Palisade Bio director buys two 10,000-share blocks

Palisade Bio, Inc. (PALI) director Donald Allen Williams reported two direct purchases of common stock: 10,000 shares at $1.4200 per share on October 1, 2026, and 10,000 shares at $1.4600 per share on October 2, 2026.

Rhea-AI Filing Summary

Palisade Bio, Inc. (PALI) director Donald Allen Williams reported two direct purchases of common stock: 10,000 shares at $1.4200 per share on October 1, 2026, and 10,000 shares at $1.4600 per share on October 2, 2026. No Rule 10b5-1 plan is reported. Separately, 3,000 shares were held indirectly through the reporting person's defined benefit plan as of October 1, 2026.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 3 txns

Insider Williams Donald Allen

Role Director

Bought 20,000 shs ($29K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.46	$15K
Purchase	Common Stock	10,000	$1.42	$14K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,590,294 shares (Direct); Common Stock — 3,000 shares (Indirect, By Reporting Person's Defined Benefit Plan)

Key Figures

Common shares purchased: 10,000 shares Price per share: $1.4200 per share Common shares purchased: 10,000 shares +2 more

5 metrics

Common shares purchased 10,000 shares Direct purchase on October 1, 2026

Price per share $1.4200 per share Direct purchase on October 1, 2026

Common shares purchased 10,000 shares Direct purchase on October 2, 2026

Price per share $1.4600 per share Direct purchase on October 2, 2026

Indirect common shares held 3,000 shares Through the reporting person's defined benefit plan as of October 1, 2026

Key Terms

Defined Benefit Plan

1 terms

Defined Benefit Plan financial

"By Reporting Person's Defined Benefit Plan"

A defined benefit plan is a retirement program that guarantees workers a specific monthly payment after they retire, with the employer responsible for funding whatever is needed to meet that promise. Investors care because these plans create long-term payment obligations that can affect a company’s cash flow and balance sheet—similar to a homeowner having a fixed mortgage the household must cover regardless of income swings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What PALI stock purchases did director Donald Allen Williams report?

Palisade Bio, Inc. director Donald Allen Williams reported direct purchases of 10,000 shares on October 1, 2026, at $1.4200 per share, and 10,000 shares on October 2, 2026, at $1.4600 per share. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 05:20 PM Accepted by SEC EDGAR 10/05/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Donald Allen

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		P		10,000	A	$1.42	1,580,294	D
Common Stock	10/02/2026		P		10,000	A	$1.46	1,590,294	D
Common Stock								3,000	I	By Reporting Person's Defined Benefit Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ryker Willie, Attorney-in-Fact for Donald Allen Williams	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)